C2N DIAGNOSTICS LLC
Blood test for early detection of Alzheimer's disease using biomarkers
- Sector
- Biotech
- Headquarters
- Saint Louis, MO
- Latest Form D
- $10M, May 2025
- Total capital
- $21.2M
- Federal grants
- $3.7M
- 5 awards · 2018–2020
- Rank in peer group#9 of 32
- Private capital raised
- $17.5M
- 2 Form D · last May 2025
- 17 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 7 pending · first 2018
- Rank in peer group#7 of 32
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$10M
- Private capital raisedForm D · SEC · 1st filing$7.5M
- Federal grantHealth and Human S · Phase II · Coverage for costs associated with reading of amyloid PET images from PARIS study$250K
- Federal grantHealth and Human S · Phase II · Plasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosis$384K
- Federal grantHealth and Human S · Phase II · Coverage for costs associated with reading of amyloid PET images from PARIS study$1.7M
- Federal grantHealth and Human S · Phase II · Plasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosis$1.1M
- Federal grantHealth and Human S · Phase II · Plasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosis$224K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
72months
from C2N DIAGNOSTICS LLC’s first federal award to its first private round.
- First federal award · May 2018
- Health and Human S · $224K
- First Form D · May 2024
- $7.5M · 1st Form D
- Awards before first raise
- 5 awards
An association in public records, not a cause or a prediction.
Standing among 32 peers
Line = medianBiotech · Instrument
- Federal grants#9 · top 28%
- Granted patents#7 · top 22%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Dr. David HoltzmanDirectorNamed in SEC Form D filings
- Dr. Joel BraunsteinExecutive Officer, DirectorNamed in SEC Form D filings
- Dr. Michael GoldblattDirectorNamed in SEC Form D filings
- Dr. Randall BatemanDirectorNamed in SEC Form D filings
- Fred MillerDirectorNamed in SEC Form D filings
- Micah OnixtExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 9- GrantedMethods For Measuring Concentrations Of Biomolecules In BiofluidsUSPTOUS 10,976,323
- PendingStable Formulations Of Humanized Anti-tau AntibodyUSPTOApplication 15735728
- PendingHumanized Anti-tau AntibodiesUSPTOApplication 15934413
Show all 9 patent records
- Methods For Measuring Concentrations Of Biomolecules In BiofluidsApr 13, 2021 · US 10,976,323Granted
- Stable Formulations Of Humanized Anti-tau AntibodyJan 30, 2020 · Application 15735728Pending
- Humanized Anti-tau AntibodiesDec 27, 2018 · Application 15934413Pending
- Methods For Extracting And Measuring Concentrations Of Biomolecules In Complex Matrices Without The Need For ImmunocaptureDec 20, 2018 · Application 15981767Pending
- Humanized Anti-tau AntibodiesMay 1, 2018 · US 9,957,317Granted
- Humanized Anti-tau AntibodiesApplication PCTUS2015038002Pending
- Methods For Measuring Concentrations Of Biomolecules In BiofluidsApplication PCTUS2018017691Pending
- Stable Formulations Of Humanized Anti-tau AntibodyApplication PCTUS2016037236Pending
- Methods For Extracting And Measuring Concentrations Of Biomolecules In Complex Matrices Without The Need For ImmunocaptureApplication PCTUS2018032901Pending
Related companies, and why
- Aplexis, Inc.Similar federal contract value in Biotech · null in contracts
- Linnaeus Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
- TARGETSITE THERAPEUTICS CORPORATIONSimilar federal contract value in Biotech · null in contracts
- I Peace, Inc.Similar federal contract value in Biotech · null in contracts
- L.E.A.F. Pharmaceuticals LLCSimilar federal contract value in Biotech · null in contracts
- LOXIGEN, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .